Q-omics provides the consensus-scored KCNE3 profile across patient tissues and cancer cell-line models. KCNE3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KCNE3 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, KCNE3 RNA expression shows 18,916 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where KCNE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNE3 survival associations across molecular data types. KCNE3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNE3 RNA expression–survival associations across cancer types. High KCNE3 expression shows unfavorable associations in LIHC, LGG, ACC and BRCA, but favorable associations in HNSC and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KCNE3 RNA expression.
This table summarizes KCNE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNE3 shows lower tumor expression in KICH, KIRP and BRCA and higher tumor expression in KIRC, LIHC and COAD. The KIRC box plot shows higher KCNE3 RNA expression in tumor versus normal tissue (log2 FC = +2.304, t-test p < 0.001).
This table shows molecular features associated with KCNE3 in patient tissues and cancer cell lines. In patient samples, KCNE3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
